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Quantiﬁcationa b s t r a c t
Besides its canonical function of catalyzing the formation of telomeric repeats, many groups have
recently reported non-canonical functions of hTERT in particular, and telomerase in general.
Regulating transcription is the central basis of non-canonical functions of telomerase. However,
unlike reverse transcriptase activity of telomerase that requires only a few molecules of enzy-
matically active hTERT, non-canonical functions of hTERT or other telomerase components
theoretically require several hundred copies. Here, we provide the ﬁrst direct quantiﬁcation of all
the telomerase components in human cancer cell lines. We demonstrate that telomerase compo-
nents do not exist in a 1:1 stoichiometric ratio, and there are several hundred copies of hTERT in
cells. This provides the molecular basis of hTERT to function in other signaling cascades, including
transcription.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Eukaryotic chromosomes are in a linear structure and the ends
of these chromosomes consist of conserved tandem repeats of DNA
known as telomeres. In these structures reside binding sites for
factors collectively termed as the ‘‘shelterin complex’’ which pro-
tects the chromosomal ends [1,2]. The length of telomeric repeats
shortens after each cell division due to the end replication prob-
lem. Cells with critically short telomeres undergo replicative
senescence, unless an enzyme specialized to add telomeric repeatscalled telomerase is functionally active. Therefore, maintenance of
the telomeres is crucial for the growth of cells [3]. It is known that
the reverse transcriptase activity of telomerase holoenzyme com-
plex is critical for maintaining telomere length. Apart from the
reverse transcriptase subunit human telomerase reverse transcrip-
tase (hTERT), the telomerase holoenzyme complex consists of a
long non-coding RNA called human telomerase RNA (hTR) (human)
or mouse telomerase RNA (Terc) (mouse) which serves as a primer
for telomere elongation; Dyskerin (DKC1) and Nucleolar Protein 10
(NOP10) [4]. In addition, other proteins like Reptin, Pontin, GAR1
ribonucleoprotein (GAR1), NHP2 ribonucleoprotein (NHP2) and
Telomerase Cajal body protein 1 (TCAB1) have been identiﬁed to
be associated with the telomerase complex transiently and it is
assumed that they play a role in its maturation and trafﬁcking
[5,6]. Unlike hTERT, expression of which is transcriptionally shut
off in all somatic cells, the other telomerase associated components
are constitutively expressed in most mammalian cell types.
Overcoming senescence and replicative immortality is a major
hallmark of cancer, and this requires the reactivation of hTERT
and hence reconstitution of telomerase activity. Indeed, muta-
tions of the hTERT promoter are known to occur in over 80% of
glioblastomas and to a lesser degree in other types of cancer
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It is believed that the hTERT promoter mutations are necessary in
cancers that arise in tissues that do not proliferate very much and
probably do not arise from the stem cell compartment [7].
Nevertheless, it is clear that 90% of human cancers show reactiva-
tion of hTERT through the activation of the hTERT promoter,
either through mutations or through other oncogenic signaling
pathways [9–14]. While it could be speculated that maintenance
of telomere ends is the primary function of the reactivated hTERT
through its function in the telomerase, several leading groups
have reported the acquisition of all other hallmarks of cancer in
cells that express hTERT [15,16]. We and others have found that
besides its canonical role in telomere length extension, hTERT
could also regulate transcription, most notably that of the onco-
genic Wnt and NFjB signaling pathways [17–19] which are well
known to regulate various aspects of cellular physiology and
oncogenesis [20,21]. This telomere independent ability of hTERT
could explain why expression of hTERT, even in its catalytically
inactive form, confers properties to cells that resemble those of
the hallmarks of cancers [22–24].
The search for the molecular basis of these non-canonical func-
tions of hTERT in particular and telomerase components in general
has led to several unexpected ﬁndings which run contradictory to
what is believed by people in the ﬁeld. hTERT has been found to
localize to the mitochondria, to inhibit apoptosis and reduce oxida-
tive stress [25]. It has been shown that hTERT can also associate
with the RNA component of mitochondrial RNA processing endori-
bonuclease (RMRP) and function as a RNA dependent RNA poly-
merase [26]. Various domains of telomerase can be separated
into those required for its canonical functions as well as its non-
canonical functions of DNA damage, cell proliferation, Wnt signal-
ing and RMRP modulation [27]. It is beginning to be accepted that
various canonical and non-canonical functions of hTERT (and other
telomerase components) function in parallel and contribute in
oncogenic transformation.
Despite the experimental evidence that the non-canonical
functions of hTERT could contribute toward oncogenic transfor-
mation, there is scepticism about the molecular basis of this
action. The key reason why these additional roles of telomerase
have been received with scepticism is because Shay and Wright
have estimated that there are only 2 molecules of hTert mRNA
in most cells and thereby extrapolated that there could only be
a few molecules of hTERT in a cell [28]. Furthermore, even to date
there is a dearth of good reagents to directly quantify hTERT
levels in cells. The presence of a few molecules of hTERT is not
a problem if the sole function of this protein is to function as a
non-metabolic enzyme, which typically has very few molecules
in a cell [29]. However, to function as a co-transcription factor
or to possess other non-canonical roles, hTERT levels in cells
ought to be much higher than that required of an enzyme.
Typical numbers of transcription factors range from a few hun-
dred to more than 10000 [30,31]. However no direct and rigorous
measurement of levels of hTERT along with other components of
telomerase has been carried out largely due to technical reasons.
Indeed it is critical to know the molar amounts of hTERT and
other telomerase components to understand if there are sufﬁcient
numbers of these to function in macromolecular complexes and
signaling pathways, besides the ones that they have known to
function in. In this manuscript we report the ﬁrst direct quantiﬁ-
cation of all telomerase components and most importantly that of
hTERT. We show that there are at least several hundred copies of
hTERT and thousands/millions of molecules of other telomerase
components in cells. These results provide the molecular basis
for non-canonical properties of telomerase.2. Materials and methods
2.1. Cell culture
A549, Hela, 293T, MCF7, HepG2 and U2OS cells were grown in
Dulbecco’s modiﬁed eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS), penicillin, streptomycin and fungi-
zone. VA13 cells were grown in DMEM, supplemented with 10%
FBS, penicillin, streptomycin and fungizone and 0.1 mM non-essen-
tial amino acids (NEAA). Cells are grown in 37 C incubator with 5%
CO2.
2.2. Plasmids and cloning for bacterial expression
pGEX-KG was used for the cloning of Reptin, Pontin, GAR1,
TCAB1, and NHP2. For the cloning of DKC1 and NOP10 together,
pETDuet-1 (Novagen) was used. C-terminal of hTERT was cloned
into pETDuet-1. All the fragments encoding above mentioned pro-
teins were ampliﬁed from cDNA prepared from 293T cells. Primer
sequences were indicated in Table 2.
2.3. Plasmid, shRNA/siRNA transfection
Plasmids overexpressing the hTert and hTR were reported ear-
lier [32]. siRNA against hTERT (ON-TARGET plus SMARTpool—
Human TERT) was purchased from Thermo Scientiﬁc (L-003547-
00-0050). Following sequences were used 50-GAACGGGCC
UGGAACCAUA-30, 50-CGCCUGAGCUGUACUUUGU-30, 50-GGUAUG
CCGUGGUCCAGAA-30, 50-GCGACGACGUGCUGGUUCA-30 for siRNA
silencing. Control siRNA was purchased from Qiagen (All Star
Negative Control). siRNA (ON-TARGET plus SMARTpool) for
Reptin, pontin, DKC1, Nop10, NHP2, TCAB1 and Gar1 were pur-
chased from Thermo Scientiﬁc. Cells were transfected using either
Lipofectamine LTX (plasmid) or Lipofectamine RNA-iMax (siRNA)
according to the manufacturer’s instructions. hTert deletion con-
structs (1–600, 1–925, 601–1127 and 350–925 amino acids) were
cloned into pBobi vector [33] at AgeI – SﬁI site. 293T cells were
transfected by deletion constructs by using Lipofectamine LTX.
2.4. Protein puriﬁcation
Sequence conﬁrmed constructs were transformed into BL21
competent cells. After IPTG induction, cells were harvested
(5000 rpm for 30 min) and lysed with lysis buffer (150 mM NaCl,
50 mM Tris and 0.5% NP40, pH7.5) with addition of protease inhibi-
tor tablet (Roche) for 30 min on ice. After incubation, cells were
sonicated for 5 min with 30 s on- 30 s off periods and centrifuged
at 18000g for 20 min at 4 C. The supernatants were incubatedwith
Ni-beads (Qiagen) or Glutathione Sepharose 4B beads (GE
Healthcare) for 1 h in a rotator incubator at 4 C. Recombinant pro-
teins were eluted with elution buffer containing 500 mM imidazole
for His-tagged proteins (150 mM NaCl, 50 mM Tris, pH 8) or with
10 mM glutathione for GST-tagged proteins. Eluted samples were
electro-eluted to remove impurities.
2.5. Western blotting
Cell numbers were quantiﬁed by hemocytometer and pelleted
and stored at 80 as 106 cells. Total protein was extracted with
Totex buffer (20 mM HEPES, pH 7.9, 0.35 M NaCl, 20% glycerol,
1% NP-40, 1 mM MgCl2, 0.5 mM EDTA, 0.1 mM EGTA) supplement-
ed with protease inhibitor cocktail (Pierce). Puriﬁed proteins were
loaded on gel with different amounts to be used as a standard for
quantitative Western blot analysis. PVDF membrane (BioRAD) was
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GAR1, TCAB1 (Santa Cruz), antibodies followed by secondary
mouse or rabbit HRP antibodies (Santa Cruz). Band intensities were
quantitated by using Image J software for densitometry analysis.
2.6. Real time telomeric repeat ampliﬁcation protocol (TRAP)
RT-TRAP assay was carried out using cell extracts equivalent to
1000 cells, 0.1 lg of telomerase primer TS supplemented with
dNTPs for 30 min at 30 C followed by PCR reaction with 50 ng
ACX primers 40 PCR cycles with 30 s at 95 C and 90 s at 60 C.
Primer sequences were indicated by Kim and Wu [34].
2.7. Immunoprecipitation and quantitative real-time PCR
Cells were lysed on ice for 20 min with lysis buffer (50 mM Tris
pH 8.0, 150 mM NaCl, 0.5% NP40, 0.5% sodium deoxycholate,
0.005% SDS supplemented with protease inhibitor cocktail and
200 u/ml RNase inhibitor). Subsequently cells were sonicated for
4 min with 30 s on/off cycles. The homogenate was centrifugated
at 13000g for 20 min at 4 C. Supernatants were incubated with
TERT, ELKS, Chk1, CD154 and IgG (Santa-Cruz) antibodies and mag-
netic protein A beads (Dynabeads-Invitrogen) for 6 h at 4 C on a
rotator. TERT bound RNAs eluted by adding Trizol reagent on
beads. Protein was eluted by boiling beads with 2 SDS sample
buffer for 10 min.
After IP reaction, cDNA reaction was performed from the elu-
tion, ﬂow-through and input fractions by Superscript cDNA VILO
kit (Invitrogen) according to manufacturer’s instructions. Real time
PCR reaction was performed by Syber Green kit (Invitrogen) for
hTR mRNA quantitation. Cq values were compared between input,
ﬂow-through and elution fractions. Percentage hTR was calculated
in elution and ﬂow-through fractions as compared to input
amount. Primers for hTR were indicated in Table 2.
2.8. Competitive PCR
Competitive hTR RNAwas cloned from hTR overexpressing plas-
mid [35]. Oligo sequences (50CGCCATGGTACCAGGCCGGGCGCCAT
GGTACCAGGCCGGG30 and reverse 50CGCCCGGCCTGGTACCATG
GCGCCCGGCCTGGTACCATGG30) were annealed and added after
position 71, following NarI (NEB) restriction enzyme digestion.
Sequence conﬁrmed construct was in vitro transcribed by T3 RNA
polymerase (Promega) and puriﬁed by phenol:chloroform extrac-
tion. Puriﬁed competitor RNA was mixed with template RNA which
was extracted from different cell types (20000 cells). Cells
were counted using hemocytometer. RNA was extracted using
TRIZOL (Qiagen) according to the manufacturer’s instructions.
Complementary DNA was prepared using Superscript Vilo reverse
transcriptase (Invitrogen) together with cell RNA using different
concentrations of competitive RNA amounts. PCR reactions were
performed in duplicate using Dreamtaq polymerase (Thermo
Fisher Scientiﬁc). FollowingPCR reaction, endogenoushTR and com-
petitive hTR products were separated on a 2% agarose gel. Band
intensities were measured by Image J software. Equal band intensi-
ties represent equal competitive and endogenous hTR. Primer
sequences are available on request.
2.9. Generation of V5-TERT 293T cells
293T cells expressing N-terminal V5-TERT were created using
the CRISPR/Cas9 method [36]. The DNA sequence of Tert (350 to
+350) was ampliﬁed and cloned into pCAG-EGFP to generate
pCAG-EGxxFP vector. Different guide RNAs (gRNAs) used for
guiding Cas9 to the speciﬁc target sequence were cloned
into pX330/Cas9 vector individually. pCAG-EGxxFP andpX330/Cas9-gRNA were co-transfected into 293T cells to verify
the gRNA target efﬁciency. The gRNA resulting in the highest
GFP+ cells was selected as a successful targeted gRNAs. To repair
genomic DNA nick created by Cas9 nuclease and insert the V5 tag
in the N-terminal of hTERT, 140 bp of oligonucleotides covering
the nick region and V5 sequence was synthesized as the repair
template. The selected pX330/Cas9-gRNA was co-transfected with
the repair template V5-TERT DNA oligonucleotide into 293T cells.
48 h after transfection, cells were seeded into 96-well plates by
limited dilution. Genomic DNA was extracted and sequenced for
veriﬁcation. DNA complementary gRNA sequence for positive col-
ony was (50CGCCCCTCGCGCGCCGATGCG30). Primers and repair
template sequences were indicated in Table 2.3. Results
3.1. Telomerase activity status of various cell lines used in the study
Before embarking on quantifying the various components of the
telomerase complex (Fig. 1A) we decided to identify cells that can
serve as controls in this analysis. We chose U2OS and VA13 cells
which have been reported to be negative for telomerase activity
[37,38] by using a TRAP assay. These cell lines are predicted to uti-
lize alternative lengthening of telomeres (ALT) for telomere elon-
gation. In addition, cancer cell lines from various origins that
possess telomerase activity and non-canonical functions of telom-
erase such as Hela (cervical cancer), 293T (kidney), MCF7 (breast),
HepG2 (liver), A2780 (ovarian) and A549 (lung cancer) were cho-
sen [18]. Real time PCR was used to assess gene expression levels
of hTR-RNA component of the telomerase enzyme- in our selected
cell lines. Unlike U2OS and VA13, all other cell lines express hTR in
a moderate level (Fig. 1B). TRAP assay showed that both VA13 and
U2OS cells have no measurable telomerase activity (Fig. 1C). To
ﬁnd out if this was due to lack of hTERT or hTR, these cells were
reconstituted with either hTR alone or with hTERT; we found that
reconstitution with both components is essential to reconstitute
telomerase activity in both these cells (Fig. 1C). These experiments
set the stage for further analysis as they suggested that (a) these 2
cells lines have no hTR or hTERT, (b) that hTR and hTERT together
are sufﬁcient to reconstitute telomerase activity and (c) that the
levels of other telomerase components are non-limiting for recon-
stitution of telomerase activity.
3.2. Quantiﬁcation of telomerase complex components
A number of proteins have been identiﬁed as part of telomerase
complex either permanently or transiently associated with it
[6,39]. However the functionality of most of these proteins and
their roles, if any, in telomerase complex and in processes away
from telomerase complex are not yet fully understood. To decipher
the stoichiometric ratio of these components under steady state
conditions, which may shed further light on their biological func-
tions. Major proteins associated with telomerase (Fig. 1A) complex
were quantitated using immuno-blotting with puriﬁed proteins as
standards [40]. A schematic of the process employed is shown in
Fig. 2A. The formula for calculation of the number of molecules is
shown in Fig. 2B. Coommassie staining of the puriﬁed proteins
and the linear curves are shown in Sup. Figs. 1 and 2, respectively.
Speciﬁcity of the antibodies against telomerase components were
shown by si-RNA knockdown strategy (Sup. Fig. 1). As a positive
control, puriﬁed beta-actin was used and the amounts of beta-actin
per cell were quantitated (Fig. 2C). Based on our analysis, 2–
4  108 molecules of Actin were estimated in the cells and this
number is close to the value reported in literature [41], suggesting
that our approach is correct.
Fig. 1. Telomerase complex and associated proteins and hTR expression and telomerase activity levels in various cell lines. (A) Representative diagram of the various
components of the telomerase complex. Proteins in solid circle comprised the core telomerase complex whereas proteins in the dotted circle are transiently associated with
telomerase. (B) hTR gene expression levels of various cancer cell types determined by RT-PCR. RNA was isolated from ﬁxed number of cells for each cell line and samples were
run in duplicates. (C) Telomerase activity was measured by TRAP assay for telomerase active cancer lines and negative cells U2OS and VA13 which were reconstituted either
with empty vector (EV), hTR or hTR + hTERT (TT) as indicated. 1000 cells were used for each reaction.
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as co-factors for transcriptional regulators due to cooperation with
chromatin remodeling proteins [42]. Furthermore they act togeth-
er for telomerase assembly [6]. Initial reports showed that Pontin
and Reptin interact and function collectively, but recently there
is evidence that these proteins can also work independently of
each other [43,44]. Based on the results presented in Fig. 3A, itwas estimated that there are about 4–6 million Pontin molecules
per cell, whereas there are about 3–5 million molecules of Reptin
per cell (Fig. 3B). NHP2, GAR1, NOP10 and DKC1 are members of
small nucleolar-ribonucleoprotein family and these proteins are
known to have role in rRNA processing and modiﬁcation. They
are localized in Cajal bodies and nucleoli. Cajal bodies are sub-or-
ganelles which are found in the nucleus of proliferative cells.
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tone mRNA processing, snRNP biogenesis and recycling. They
recruit RNA to be extended by telomerase at the end of telomeres
[45]. Calculations employing the mentioned technique showed
that there are 400000 molecules of NHP2 per cell (Fig. 3C) whereas
there are around 50000 molecules of GAR1 (Fig. 3D) per cell. The
levels of NOP10 were estimated to be about 100000 molecules
per cell (Fig. 3E). DKC1 levels range between 0.5 and 1 million
molecules per cell (Fig. 3F). TCAB1 is a Cajal body RNA chaperone
which is known to bind to hTR. This assembly results inFig. 2. Flowchart and calculation formula for the quantiﬁcation of telomerase associated
telomerase components. Telomerase complex proteins were cloned from cDNA in pETDu
BL21 strain and optimized for expression conditions. (⁄NOP10 was cloned to pETDuet1 v
and tagged proteins were puriﬁed using afﬁnity puriﬁcations as discussed in methods s
(WB). Impurities were eliminated by electro-eluting desired protein from SDS–PAGE g
titration optimization with the respective antibodies. Quantitative WB was performed by
immunoblot which were determined by hemocytometer counting. Cell numbers vary ac
bands were measured by Image J software. (B) Calculation formula for quantitative W
used to obtain linear curve and function to compare with the bands of cell lines. Obta
(C) Quantitation of Actin in human cancer cell lines. Puriﬁed Actin was titrated for immrecruitment of telomerase to the telomeres. Recent reports show
TCAB1 also has Cajal body independent recruitment roles for
telomerase to the telomeres [46]. The numbers of TCAB1 molecules
in cancer cells are estimated to be about 3 to 4 million per cell
(Fig. 3G). Non speciﬁcity of the Telomerase Cajal body protein 1
(TCAB1) antibody tested, makes it difﬁcult to perform these calcu-
lations. It must be noted that depending on the quality of the avail-
able antibodies and their afﬁnities and avidities, different amounts
of standards was used to obtain standard curves. The estimated
numbers of these molecules in various cancer cell lines andproteins. (A) Flowchart showing puriﬁcation and quantiﬁcation strategy for various
et1 (His-Tag) and pGEX-KG (GST-Tag) vectors. These vectors were transformed into
ector with DKC1 to increase folding capabilities.) Cells were cultured on large scale
ection. Purity proﬁle was controlled by Coomassie blue staining and Western blots
els. Puriﬁed proteins were used as a standard for quantitative Western blots after
running standards and cell lysates together. We used ﬁxed number of cells for each
cording to expression levels and efﬁciency of antibodies. Intensities of Western blot
estern blot. Western blot band intensities and protein amounts of standards were
ined values were applied to the formula to obtain number of molecules per cell.
unoblotting experiment along with cell lysates as indicated.
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similar level of these proteins in telomerase positive and negative
cells indicates that these proteins do most likely have other func-
tions apart from those of that required in the telomerase complex.
Furthermore, given that there is a huge variation in the number of
these proteins in all the cells irrespective of their telomerase activ-
ity status, it adds to the notion that only a few molecules of telom-
erase complex have all these proteins incorporated exist in cells,
and the rest of the molecules of these proteins incorporated,Fig. 3. Quantiﬁcation of telomerase components in various cell lines. Puriﬁed proteins w
according to the antibody detection limit and expression levels in cell lines. Amount of p
molecule numbers per cell showed by bar graphs for different cell lines. Intensities of W
(B), DKC1 (C), GAR1 (D), NHP2 (E), TCAB1 (F) and NOP10 (G) by immunoblotting was rep
for NHP2 and TCAB1 and 400000 cells for NOP10 were loaded equally for each cell linewhereas the rest of the molecules of these proteins most likely
have telomerase independent roles in other macromolecular
complexes.
3.3. Quantiﬁcation of hTERT
Quantiﬁcation of hTERT has been an important unsolved prob-
lem due to two reasons, ﬁrstly, being the lack of good antibodies
that recognizes the endogenous protein coupled with seeminglyere used as a standard for quantitation by immunoblotting. Standards were titrated
rotein standards used for Western blots have been indicated in Sup. Fig. 2. Protein
estern blot bands measured by Image J software. Quantitation of Pontin (A), Reptin
resented. Lysates from 10000 cells for Pontin, Reptin, DKC1 and GAR1, 200000 cells
. These data are representative of two independent experiments. FL: full length.
Table 2
Primer sequences.
Pontin Forward
Pontin Reverse
AGATCTAGACATGAAGATTGAGGAGGTGAAGAGC
AGAAAGCTTTCACTTCATGTACTTATCCTGC
Reptin Forward
Reptin Reverse
AGATCTAGACATGGCAACCGTTACAGCCA
AGAAAGCTTTCAGGAGGTGTCCATGGTCTCG
Dyskerin Forward
Dyskerin Reverse
AGAAAGCTTCTACTCAGAAACCAATTCTACCTCTTT
AGAGAATTCCATGGCGGATGCGGAAG
Nop10 Forward
Nop10 Reverse
AGACATATGATGTTTCTCCAGTATTAC
AGACTCGAGTCAGAGGACAGGGCGCG
Tert Forward
Tert Reverse
AGAGAATTCGATGCCGCGCGCTCCCC
AGAAAGCTTCTAGTCCAGGATGGTCTTGAAGTC
NHP2 Forward
NHP2 Reverse
AGATCTAGACATGACCAAAATAAAGGCGATCCCGA
AGAAAGCTTTCATAGGGGTAGGGGCAGGGACTGC
Gar1 Forward
Gar1 Reverse
AGATCTAGACATGTCTTTTCGAGGCGGAGGTCG TG
AGAAAGCTTTTAATGTCCTCTCCCTCTGA
Tcab1 Forward
Tcab1 Reverse
AGATCTAGACATGAAGACTTTGGAGACTCAACCGT
AGAAAGCTTTTATATCAGCTCACCCACACCT
Antisense repair DNA
oligo with V5 tag
TAGTGGCTGCGCAGCAGGGAGCGCACGGCTCGGCAG
CGGGGAGCGCGCGGGGTGCTGTCCAGGCCCAGCAG
GGGGTTGGGGATGGGCTTGCCCATGGCGGGGGTGGCC
GGGGCCAGGGCTTCCCACGTGCGCAGCAGGACGC
gRNA1 CGCCCCTCGCGCGCCGATGCG
gRNA2 CCCTCGCGCGCCGATGCGCCC
hTR qpcr Forward
hTR qpcr Reverse
TCTAACCCTAACTGAGAAGGGCGTAG
GTTTGCTCTAGAATGAACGGTGGAAG
Table 1
Molecule numbers per cell for each protein in 8 different cancer cell line. Numbers were rounded to the nearest thousand.
Cells Proteins
293T Hela MCF7 HepG2 A549 A2780 U2OS VA13
Actin 89898000 368484000 224623000 157737000 171875000 138343000 260648000 228814000
Pontin 6548000 4012000 4350000 4488000 4181000 4526000 3474000 3504000
Reptin 3978000 5310000 3330000 3181000 2809000 3589000 2987000 3618000
NHP2 260000 600000 370000 434000 132000 376000 438000 350000
GAR1 57000 58000 69000 78000 27000 63000 49000 69000
NOP10 121000 130000 144000 134000 133000 127000 108000 104000
DKC1 754000 731000 669000 672000 446000 624000 574000 510000
TCAB1 3763000 4322000 4588000 4055000 4507000 3949000 3177000 3580000
980 S.C. Akıncılar et al. / FEBS Letters 589 (2015) 974–984low amounts of this protein. Secondly, most hTERT antibodies
detect a non-speciﬁc band that runs around the same position as
the endogenous hTERT under all protein electrophoresis conditions
examined [47]. Unlike the detection of the endogenous hTERT,
detection of overexpressed hTERT using a number of hTERT anti-
bodies is not difﬁcult. But for careful quantiﬁcation purposes, an
antibody that speciﬁcally recognizes the endogenous hTERT pro-
tein is needed. Due to this reason various hTERT antibodies were
tested before we decided to use Abcam monoclonal hTERT anti-
body (Sup. Fig. 3) as it was the best in detecting reduced TERT
levels in siTERT cells and is a monoclonal with a deﬁned epitope.
To quantify hTERT accurately, a puriﬁed hTERT protein was need-
ed. However, similar to what Matsutomi et al. observed, we are
unable to purify full-length hTERT from Escherichia coli [48]. We
also tried to purify full-length hTERT from Pichia pastoris but failed
to do so. To circumvent this problem, we undertook to characterize
a fragment of hTERT that is soluble and would be recognized by the
Abcam antibody of choice. To do this, a series of Flag-tagged hTERT
deletion constructs transfected into HEK293T cells, was used to
identify the portion of hTERT that is recognized by the monoclonal
antibody. Sup. Fig. 4A shows that the hTERT monoclonal antibody
of choice recognizes a domain in amino acids 926–1127 of hTERT
(the C-terminus of hTERT). Hence, the C-terminal of hTERT was
cloned into pET-Duet and this fragment puriﬁed for use as a stan-
dard in immunoblotting (Sup. Fig. 4B).
Based on the analysis in Sup. Fig. 4C, we quantitated about
60000–100000 total hTERT molecules per cell across cell lines
(Sup. Fig. 4C and D), which is more than what others [28,49] have
estimated. This 127kDahTERTbandwhichwas detected by the anti-
bodycouldbeanon-speciﬁcbandconsistingof hTERTandotherpro-
teins as the best hTERT antibody could detect a band even in
telomerase negative cell lines like U2OS and VA13. To solve this
issue ﬁrst, mass spectrometry was carried out to quantitate the
amount of endogenous hTERT in cells (data not shown). However,
due to the presence of many other more abundant proteins with
around the samemolecularweight, we are unable to detect endoge-
noushTERTbymass spectrometry, except only inHela cells express-
ing a TERT overexpression plasmid (data not shown). Apart from
thesemethods, a CRISPRN’ V5-TERT knock-in 293T cell linewas cre-
ated to eliminate the non-speciﬁc antibody problem (Sup. Fig. 5A). It
was hoped that the endogenous TERT could be quantitated by the
use of V5 antibody by this method. Unfortunately, we observed that
the transcription level of hTERT (Sup. Fig. 5B) and TRAP activity in
this N’ V5-TERT knock-in 293T cell line was 5 fold reduced as com-
pared to WT 293T cells (Sup. Fig. 5C). Therefore, we concluded that
the V5 tag at the N terminal affects expression of hTERT transcripts
which prevents us to use it as a quantiﬁcation tool.
3.4. Quantiﬁcation of hTR and back calculation of hTERT
Since the number of hTERT quantiﬁed based on our antibody
approach was far greater than that of the previous estimates orreports, and since all other possible approaches failed as indicated
above, another approach was needed to verify this ﬁnding. Based
on the fact that TERT associates 1:1 with hTR [4,49], a novel
method to immunoprecipitate (IP) hTERT from cells and quantify
the amount of hTR bound to it was carried out. In this approach,
cells were counted prior to IP reaction to equalize input and output
(elution + ﬂow-through). RNA isolation was carried out from the
input (10%), ﬂow-through, wash and elution fractions and quanti-
tative real time PCR performed for hTR. The input was set to 100%
and the elution and ﬂow-through fractions were normalized to it.
From this result, the percentage distribution of hTR in elution
(hTERT bound hTR) and ﬂow-through (hTERT free hTR) could be
calculated and hence back calculation of the amount of hTERT from
the amount of hTR pulled down by the hTERT antibody (Fig. 4A)
could be carried out. The amount of endogenous hTR molecules
was estimated using competitive semi-quantitative PCR (Fig. 4B).
Competitive PCR allows for more precise quantiﬁcation of RNA as
it relies on competitor RNA which is subjected to similar RT and
PCR conditions as the template and it will not be inﬂuenced by
the quality of the initial template and tube-to-tube variation dur-
ing ampliﬁcation [50]. Based on the calculations presented, the
estimated amount of hTR is 11478(±1230) for Hela and
17218(±1570) for 293T and 0 molecules per cell for U2OS cell line
(Fig. 4B). To evaluate the speciﬁcity of the TERT antibody in native
IP conditions, irrelevant antibodies including those to ELKS, Chk1
and CD154 were used besides the IgG control antibody on control
Hela cells and TERT overexpressing Hela-TERT cells. As compared
to irrelevant antibodies which did not pull down either TERT or
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(Fig. 4C), suggesting that the hTERT antibody works very well with-
out non-speciﬁc interactions (unlike in theWestern blots) in native
IP conditions (Fig. 4C). IP result indicated that 5.79% (±0.5%) of total
endogenous hTR molecules were detected in the elution fraction
which equates to around 665 hTR and by equivalence, 665 hTERT
molecules in a cell (Fig. 4D). Calculation of this number comes from
the number of total hTR molecule in Hela cells which is 11478
(Fig. 4B). This number obtained is solely RNA bound hTERT num-
bers, and as there are possibly hTR unassociated hTERT moleculesFig. 4. Competitive PCR for hTR quantiﬁcation and hTERT quantitation. (A) Schematic re
was pulled down by the hTERT antibody and RNA was extracted from elution and ﬂow
According to 1:1 TERT-hTR interaction in the cell, number of hTR molecules is equal to
were spiked in to template RNA which was equivalent to 20000 cells with decreasing am
into a 2% agarose gel. Competitor RNA (166 bp) and endogenous RNA (126 bp) were separ
RNA were equal to 293T and Hela hTR expression respectively, whereas U20S cells
overexpression) cell lines immunoprecipitated with TERT antibody (EV: empty vector). I
input ﬂow through and elution fractions kept for RNA isolation for quantitative real time
and Cq values of the fractions were compared and represented as percentage amounts o
through. IP: Immunoprecipitation.) These data are representative of three independentin the cell, it can be surmised that at least 665 molecules of hTERT
exist in these cells while the actual number could be far greater.
Additionally, the IP results showed that 5–6 times more hTR and
hTERT molecules in hTERT overexpressing Hela cells were trapped
compared to control Hela cells (Fig. 4D). Western blot and SILAC
experiments showed that the overexpression results in 6 fold high-
er expression of TERT compared to control Hela cells (data not
shown). Taken together, these two results suggest that our
methodology is working in the linear range and the levels of hTR
and hence hTERT quantitated this way is accurate. As stated above,presentation of hTERT quantiﬁcation through hTR back calculation. hTERT molecule
-through fractions. Percentage hTR was calculated as compared to input hTR RNA.
hTERT molecules. (B) In vitro transcribed hTR RNA 200 pg, 100 pg, 50 pg and 25 pg
ounts for cDNA reactions and followed by PCR reactions. PCR products are loaded
ated and intensities were compared by Image J software. 75 pg and 50 pg competitor
did not express hTR as expected. (C) Hela control (EV) and Hela-TERT (hTERT
gG, Chk1, ELKS and CD154 antibodies were used as negative controls. Samples from
PCR experiment. (D) Quantitative real time PCR was performed for hTR expression
f hTR in elution (TERT bound) and ﬂow through (free-unbound) fractions. (FT:Flow-
experiments.
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and since the quantiﬁcation of hTERT is dependent on the speciﬁci-
ty of the hTERT IP, a TERT IP was performed using U20S cells which
have no detectable hTERT or hTR (Fig. 1B and C). As shown in Sup.
Fig. 6, the anti-hTERT antibody could only IP hTR from U20S cells
that are reconstituted with both TERT and hTR (Sup. Fig. 6).
These results showed that the TERT antibody of choice is excellent
for IP and it speciﬁcally brings down hTR thus raising the level of
conﬁdence in our quantiﬁcation of hTERT described in Fig. 4.
4. Discussion
There have been a few previous attempts to quantitate the
amount of telomerase molecules in cells. Yi et al. [28] quantitated
+a+b hTERT mRNA as an extrapolation to calculate the number of
catalytically active telomerase molecules in a cell to be about 600
molecules. This +a+b form has no mutation on its reverse tran-
scriptase (RT) site and therefore is catalytically active, whereas
the alternatively spliced a or b containing forms have muta-
tions on the a or b sites of the RT motif respectively, rendering
hTERT catalytically inactive. However, it was noted that only 5%
of hTert mRNA is in the +a+b form, and 95% of hTert mRNA does
not produce active telomerase (+ab, ab, a+b forms). Cohen
et al. [49] used an afﬁnity puriﬁcation to pull down hTERT followed
by a telomere repeat primer to pull down active telomerase, ﬁnally
arriving at an estimate of around 20–40 molecules of active
telomerase per HEK293T cell. These methods are mainly used to
provide an estimate of catalytically active telomerase molecules
in a cell. Xi et al. quantitated hTERT using IP and western by two
different hTERT antibodies [51]. Although they arrive at a similar
number of hTERT molecules as us, we predict that the number of
hTERT molecules is at least 2–5 times higher than that predicted
by both studies as our method only traps hTR bound TERT. The
limitation of the antibody used in that study could also be a reason
why the estimates vary.
However, a few groups have noted that catalytically inactive
telomerase can have other functions in a cell. This makes sense,
as producing 95% of inactive telomerase is a waste and natural
selection would have eliminated alternative splicing of hTERT if
it does not serve any useful function. Supporting this, Hrdlicková
et al. [52] found that alternative spliced telomerase can stimulate
cell proliferation. Park et al. [17] reported that inactive telomerase
can stimulate the Wnt signaling pathway whereas Ding et al. [53]
showed that inactive telomerase can still bind p65 and regulate
NFjB signaling. Also, a HA-tagged hTERT that could not elongate
telomeres was found to protect against apoptosis [54]. Lastly, a
16 amino acid sequence of the catalytically active site of hTERT,
GV1001, was found to be sufﬁcient to confer extra-telomeric func-
tions, in the absence of canonical telomerase activity in cells [55].
As the anti-hTERT antibodies in the ﬁeld against hTERT are not
very speciﬁc, we circumvented this problem by estimating the
amount of hTR in a cell and calculating the amount of hTR pulled
down by anti-hTERT antibody. From the ﬁrst part of the study,
we estimated the amount of hTR in a cell to be from 0 in the telom-
erase negative cell lines U2OS and VA13 to about 11000–17000 in
the telomerase active cell lines. From our immune-precipitation
experiments, we established that about 6% of hTR is pulled down
together with hTERT and from this we back calculated the amount
of hTERT to be about 665 per cell. It is important to note that the
technical aspects of hTR quantiﬁcation make the quantiﬁcation of
TERT very difﬁcult as a large proportion of hTR is degraded during
the IP procedure. The number of hTR and TERT found in these stud-
ies is a gross underestimation from the actual numbers that exist in
cancer cells. However these numbers, since they are derived from
direct methods and not from extrapolations tell us that at leastseveral hundred molecules of TERT do exist in cells, which could
easily be sufﬁcient for them to function in pathways apart from
telomere elongation. With this large number of hTERT molecules
present in the cell; we believe that telomerase can possess many
other roles, independent of its enzymatic activity. Thus, hTERT
could possibly act as a transcriptional co-factor in oncogenesis.
Compared to previous methods of hTERT quantitation [28,49],
our method of telomerase estimates total hTERT protein amounts,
regardless of whether it is catalytically active or not. Whereas Yi
et al. and Cohen et al. extrapolated the number of catalytically
active hTERT molecules based on mRNA quantitation of hTERT
and afﬁnity puriﬁcation of active hTERT respectively and this will
not reﬂect the true total number of inactive hTERT molecules that
could serve other non-canonical functions of telomerase.
This study also suggest that the number of the various telom-
erase components in a given cell type varies signiﬁcantly
(Table 1), suggesting that besides association with the telomerase
complex, these components have telomerase independent roles.
Dyskerin possesses a role in p53 biogenesis as well as ribosome
function [56]. The amount of DKC1 was 2 times higher than that
of NHP2 and 10 times higher than that of GAR1, showing that
besides being associated with NHP2, GAR1 and NOP10 to form
the telomerase complex, DKC1 could possibly have other roles in
the cell. Besides telomerase assembly, Reptin and Pontin exhibits
diverse functions as components of protein complexes, with roles
in chromatin remodeling, transcriptional regulation, DNA damage
repair, etc [57,58]. Pontin and Reptin are involved in chromatin
remodeling complexes [58], and it was found that they can form
hetero-dodecamers [59], homo-oligomers [60,61]. Although they
are commonly associated with the same chromatin remodeling
complexes like INO80, SRCAP, Tip60, they may have functions
independently of each other [62] and may also repress each other’s
role in transcriptional regulation. In conclusion, this study shows
that the various components of telomerase do not exist in stoichio-
metric ratios of 1:1. It also shows that there are enough hTERT
molecules to carry out non-canonical roles of telomerase in cells,
probably in transcription.
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